Ondine Biomedical Inc.

OTCPK:OBIM.F Stock Report

Market Cap: US$43.4m

Ondine Biomedical Past Earnings Performance

Past criteria checks 0/6

Ondine Biomedical has been growing earnings at an average annual rate of 31.4%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 103.2% per year.

Key information

31.4%

Earnings growth rate

59.1%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate103.2%
Return on equity-75,126.3%
Net Margin-873.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ondine Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:OBIM.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242-1496
31 Mar 241-1496
31 Dec 231-14105
30 Sep 231-17115
30 Jun 231-19126
31 Mar 231-19126
31 Dec 221-19126
30 Sep 221-37146
30 Jun 221-54165
31 Mar 222-52155
31 Dec 213-50135
31 Dec 202-16123

Quality Earnings: OBIM.F is currently unprofitable.

Growing Profit Margin: OBIM.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OBIM.F is unprofitable, but has reduced losses over the past 5 years at a rate of 31.4% per year.

Accelerating Growth: Unable to compare OBIM.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OBIM.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: OBIM.F has a negative Return on Equity (-75126.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:41
End of Day Share Price 2024/10/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ondine Biomedical Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew SimmsArden Partners Plc.
David DeanCormark Securities Inc.
Charles WestonRBC Capital Markets